Renaming schizophrenia: why, how, and what next?

被引:0
|
作者
Mesholam-Gately, Raquelle I. [1 ,2 ]
Nagendra, Arundati [3 ]
Keshavan, Matcheri [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA USA
[2] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[3] Schizophrenia & Psychosis Act Alliance, Alexandria, VA USA
关键词
discrimination; renaming; schizophrenia; stakeholder-oriented research; stigma; NAME CHANGE; STIGMA; PSYCHIATRISTS; PEOPLE; JAPAN;
D O I
10.1097/YCO.0000000000001002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of reviewThe debate over renaming schizophrenia has gained international momentum, driven by concerns about stigma and scientific accuracy. This review examines the arguments for and against renaming schizophrenia, highlighting research data from the US and international efforts.Recent findingsProponents argue that the current term perpetuates stigma, is scientifically outdated, and that stakeholders, including those with lived experience, favor a name change. Opponents, however, caution that renaming might not reduce stigma and could complicate access to care. Stigma associated with schizophrenia leads to significant discrimination in healthcare, employment, and social interactions. Moreover, the term inaccurately suggests a 'split' in the brain, contributing to public misconceptions. Survey data from various countries reveal substantial support for renaming, with some evidence suggesting that new terms can reduce stigma and improve treatment engagement. Historical precedents, such as the renaming of multiple personality disorder to dissociative identity disorder, show that such changes can occur without disrupting care.SummaryThe review concludes that while renaming schizophrenia could align the term with contemporary science and reduce stigma, a systematic, consensus-building approach involving diverse stakeholders is essential. Future steps should focus on finding an appropriate name that reflects the illness's core aspects and ensures optimal care.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 50 条
  • [21] HOW TO, WHAT, AND WHY
    LINVILLE, LB
    AMERICAN BAR ASSOCIATION JOURNAL, 1982, 68 (NOV): : 1344 - 1344
  • [22] GOBAL SURVEY OF RENAMING OF SCHIZOPHRENIA
    Maruta, T.
    Matsumoto, C.
    Iimori, M.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [23] Renaming the term schizophrenia in Japan
    Iwadate, T
    Kawamuro, Y
    Nishimura, Y
    Moriyama, K
    Ono, Y
    Oshima, I
    Takagi, S
    Ushijima, S
    Kim, Y
    LANCET, 2002, 360 (9336): : 879 - 879
  • [24] IMMUNOTHERAPY IN SCHIZOPHRENIA: WHAT ARE THE NEXT STEPS?
    Weiser, Mark
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S86 - S86
  • [25] Renaming schizophrenia in South Korea
    Lee, Yu Sang
    Kim, Jae-Jin
    Kwon, Jun Soo
    LANCET, 2013, 382 (9893): : 683 - 684
  • [26] #METOO: WHY NOW? WHAT NEXT?
    Rhode, Deborah L.
    DUKE LAW JOURNAL, 2019, 69 (02) : 377 - 428
  • [27] CHEMOMETRICS, WHY, WHAT AND WHERE TO NEXT
    WOLD, S
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (08) : 589 - 596
  • [28] LIS Accreditation: Why and What Next?
    Applegate, Rachel
    LIBRARY TRENDS, 2022, 71 (01) : 21 - 35
  • [29] Renaming schizophrenia: a Japanese perspective
    Sato, Mitsumoto
    WORLD PSYCHIATRY, 2006, 5 (01) : 53 - 55
  • [30] Why, when and how to screen for cognitive difficulties in the clinic-And what to do next?
    Miskowiak, K.
    Yatham, L.
    BIPOLAR DISORDERS, 2020, 22 : 24 - 24